Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
UBS
US Department of Justice
Argus Health
Daiichi Sankyo
McKinsey
Fish and Richardson
Novartis
Medtronic

Generated: February 19, 2018

DrugPatentWatch Database Preview

Glaxo Grp England Company Profile

« Back to Dashboard

Summary for Glaxo Grp England
International Patents:145
US Patents:10
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Glaxo Grp England

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 7,498,440 ➤ Sign Up Y Y ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 8,113,199 ➤ Sign Up Y ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 8,746,242 ➤ Sign Up Y ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 8,201,556 ➤ Sign Up Y ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 8,183,257 ➤ Sign Up ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 7,488,827 ➤ Sign Up Y Y ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 8,534,281 ➤ Sign Up Y ➤ Sign Up
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes 8,161,968 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Glaxo Grp England

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,575,347 Muscarinic acetylcholine receptor antagonists ➤ Sign Up
9,144,571 Muscarinic acetylcholine receptor antagonists ➤ Sign Up
8,853,404 Muscarinic acetylcholine receptor antagonists ➤ Sign Up
9,045,469 Muscarinic acetylcholine receptor antagonists ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Glaxo Grp England Drugs

Country Document Number Estimated Expiration
Australia 2006324478 ➤ Sign Up
Mexico 2008001250 ➤ Sign Up
China 1829547 ➤ Sign Up
Japan 5014121 ➤ Sign Up
Canada 2755954 ➤ Sign Up
Denmark 1730676 ➤ Sign Up
Norway 20065417 ➤ Sign Up
Japan 2008509766 ➤ Sign Up
Israel 178152 ➤ Sign Up
South Africa 200606421 ➤ Sign Up
Country Document Number Estimated Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Glaxo Grp England Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
8 50012-2014 Slovakia ➤ Sign Up PRODUCT NAME: UMEKLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922/001 - EU/1/14/922/003 20140430
1740177/02 Switzerland ➤ Sign Up PRODUCT NAME: UMECLIDINIUM BROMID + VILANTEROL; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014
0694 Netherlands ➤ Sign Up PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140430
2014038 Lithuania ➤ Sign Up PRODUCT NAME: UMECLIDINIUM BROMIDIUM; REGISTRATION NO/DATE: EU/1/14/922 20140428
1740177/03 Switzerland ➤ Sign Up PRODUCT NAME: UMECLIDINIUM BROMID; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014
00694 Netherlands ➤ Sign Up PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428
2014038,C1740177 Lithuania ➤ Sign Up PRODUCT NAME: UMEKLIDINO BROMIDAS; REGISTRATION NO/DATE: EU/1/14/922 20140428
2014000096 Germany ➤ Sign Up PRODUCT NAME: UMECLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428
0140032 00132 Estonia ➤ Sign Up PRODUCT NAME: UMEKLIDIINBROMIID;REG NO/DATE: EU/1/14/922 30.04.2014
565 Luxembourg ➤ Sign Up PRODUCT NAME: BROMURE D'UMECLIDINUM; FIRST REGISTRATION DATE: 20140428
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Accenture
Citi
Boehringer Ingelheim
Cantor Fitzgerald
Mallinckrodt
Merck
Argus Health
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot